WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer

Inclusion Criteria

• •Patients should have a histological diagnosis of primary ovarian, fallopian tube, or primary peritoneal carcinoma and have undergone chemotherapy according.
• •Initial attempted cytoreductive surgery must have been performed by gynecologic oncologist with strict adherence to GOG surgical manual.
• •End result of first surgery must have been optimal cytoreduction as defined as no residual tumor ≥ 1cm.
• •Patients should have clinical evidence of first recurrence. Two fold elevations in CA125 or measurable tumor on CT scan constitute adequate evidence of recurrent disease.
• •Patients with the following primary tumor epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, adenocarcinoma (non-specific) NOS, mixed epithelial carcinoma.
• •Patients must have platin sensitive disease, defined as a recurrence occurring greater than 6 months from cessation of original treatment.
• •Patients must have a performance status of 0, 1, 2.
• •Patients must have adequate bone marrow function as defined by an absolute neutrophil count (ANC) ≥1500, platelet count ≥ 100,000, and a hemoglobin of greater than 10g/dl.
• •Patients must have adequate renal function as defined by serum creatinine ≤ 1.5 mg/dl.
• •Patients must have adequate hepatic function as defined by bilirubin ≤ 1.5 times normal levels, alkaline phosphatase and SGOT ≤ 3 times normal levels.
• •Patients who have signed an Institutional Review Board (IRB) approved informed consent.
• •Female patients 16-90 years of age.
• •Patients must be deemed medically able to undergo a secondary surgical procedure.
• •Patient eligibility for systemic chemotherapy following HIPC:
• •Patients must have successfully completed HIPC within 6 weeks of first prescribed intravenous carboplatin and taxane cycle.
• •Patients must have a performance status of 0, 1, or 2.
• •Patients must have adequate bone marrow function as defined as an ANC ≥ 1500, platelet count ≥ 100,000, and a hemoglobin of greater than 10g/dl.
• •Patients must have adequate renal function as defined by serum creatinine ≤ 1.5 mg/dl.
• •Patients must have adequate hepatic function as defined by bilirubin ≤ 1.5 times normal levels, alkaline phosphatase and SGOT ≤ 3 times normal levels.
• •Patients who have signed an IRB approved informed consent.